GREENWICH, CT - Southfield Capital, a leading lower middle market private equity firm, announced today that it has completed the sale of BioPharm Communications (“BioPharm”) to Omnicom Health Group. BioPharm is a leading communications agency that specializes in proprietary, multichannel marketing programs to physicians and healthcare practitioners for pharmaceutical and biotechnology clients.
Southfield Capital acquired BioPharm in 2012 in partnership with the company’s two founders, Jeff Persinger and Daniel Egeland. During Southfield’s ownership, BioPharm experienced tremendous growth. The company’s exceptional performance is primarily attributed to the broadening of its product suite, the expansion and institutionalization of the sales organization and the augmentation of the leadership team. The sale represents a very successful exit for Southfield’s investors and the management shareholders.
“Southfield was a fantastic partner, not only from a financial perspective but also from a strategic standpoint, and the Southfield team made significant contributions to our growth over the past four years," said Jeff Persinger, President and CEO of BioPharm.”
Heb James, a Partner with Southfield Capital, commented on the sale, “This outstanding exit is clear validation of the incredible value the talented team at BioPharm has created over the last few years. It’s been such a pleasure working with the folks at BioPharm. They should be very proud of their accomplishments, and I wish them the best of luck with Omnicom.”
The acquirer, Omnicom Health Group, is the largest healthcare marketing and communications group in the world.
Petsky Prunier acted as the financial advisor to BioPharm. Finn Dixon & Herling acted as legal advisor to BioPharm.
Founded in New Hope, PA in 2005, BioPharm Communications (www.biopharmcommunications.com) helps brand teams at pharmaceutical and biotech companies execute customized marketing campaigns through a comprehensive portfolio of proprietary program offerings. As part of a customized 360º strategy, BioPharm educates healthcare professionals through the Peer-to-Peer360º suite, differentiates and builds brand awareness through the brand360° campaign approach, and tracks engagement instantly via the Insights360° CRM platform.
About Southfield Capital
Southfield Capital is a private equity firm that invests in exceptional, growing companies in the lower middle market. The firm makes control investments in North American companies generating $4 - 12 million in EBITDA with proven business models, attractive growth and profitability trends, and strong leadership. For more information, please visit www.southfieldcapital.com.
Heb James, Partner